CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Phase 2
94
about 7 years
18+
1 site in IL
What this study is about
This trial is testing a treatment with CPI-613, hydroxychloroquine, and either 5-fluorouracil or gemcitabine for advanced solid tumors that have not responded to chemotherapy. The goal is to see if this combination can help slow the growth of these tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Devimistat
- 2.Take Fluorouracil
- 3.Take Gemcitabine Hydrochloride
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), hydroxychloroquine (Antimalarial; increases pH in parasite)
oral (Oral Capsule), oral
Primary: Overall response rate (ORR)
Secondary: Duration of response (DOR), Incidence of adverse events, Overall survival (OS), Progression free survival (PFS)
diagnostic, imaging
Oncology, Respiratory